Knights of Columbus Asset Advisors LLC Has $3.44 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Knights of Columbus Asset Advisors LLC lifted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 101.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 116,644 shares of the company's stock after acquiring an additional 58,773 shares during the period. Knights of Columbus Asset Advisors LLC owned 0.25% of Mirum Pharmaceuticals worth $3,443,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its position in shares of Mirum Pharmaceuticals by 98.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company's stock worth $31,000 after acquiring an additional 488 shares during the last quarter. Royal Bank of Canada grew its position in Mirum Pharmaceuticals by 40.1% in the 2nd quarter. Royal Bank of Canada now owns 1,851 shares of the company's stock valued at $48,000 after buying an additional 530 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Mirum Pharmaceuticals by 186.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company's stock valued at $48,000 after buying an additional 1,202 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in Mirum Pharmaceuticals in the 1st quarter valued at about $49,000. Finally, Ameritas Investment Partners Inc. grew its position in Mirum Pharmaceuticals by 85.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,208 shares of the company's stock valued at $57,000 after buying an additional 1,016 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 1.0 %

MIRM stock traded up $0.24 during mid-day trading on Friday, reaching $23.81. 336,931 shares of the stock traded hands, compared to its average volume of 426,483. The company has a current ratio of 4.45, a quick ratio of 4.19 and a debt-to-equity ratio of 1.23. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.29 and a 52-week high of $35.56. The company has a market cap of $1.12 billion, a P/E ratio of -6.00 and a beta of 1.14. The stock's fifty day moving average is $26.89 and its 200-day moving average is $28.48.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The firm had revenue of $69.55 million for the quarter, compared to analysts' expectations of $66.73 million. As a group, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. SVB Leerink decreased their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an "outperform" rating for the company in a research report on Monday, March 18th. JMP Securities upped their price target on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Thursday, March 14th. Stifel Nicolaus initiated coverage on shares of Mirum Pharmaceuticals in a report on Wednesday. They issued a "buy" rating and a $48.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $58.00 price target on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $35.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $51.70.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the company's stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares of the company's stock, valued at $748,535.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, COO Peter Radovich sold 4,303 shares of the stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares of the company's stock, valued at $748,535.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eric Bjerkholt purchased 2,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 18th. The stock was bought at an average cost of $25.80 per share, with a total value of $51,600.00. Following the completion of the transaction, the chief financial officer now directly owns 12,000 shares of the company's stock, valued at $309,600. The disclosure for this purchase can be found here. Insiders own 24.06% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.